The gains in the global fight against tuberculosis have been threatened as a result of the COVID-19 pandemic, including a diversion of resources that have led to disruptions in ongoing research and control programs.
In a general population of patients with latent TB infection (including patients with and without HIV), studies have confirmed the superior safety profile of treatment with rifampicin vs isoniazid.
Whole genome sequencing of M tuberculosis isolates can identify complete drug susceptibility profiles, allowing precise treatment in early TB infection.
Study authors conducted a systematic review and meta-analysis to assess diagnostic accuracy of Xpert Mycobacterium tuberculosis (MTB)/rifampin(RIF) on stool for pediatric tuberculosis.
Study authors assessed the relationship between children living in contact with sputum smear-positive tuberculosis patients on DOTS and children getting infected with tuberculosis or tubercular infection.
The randomized, open-label, controlled trial (Study 31/A5349) had more than 2500 participants ages 12 years and older and included 214 people with HIV.
New study published in the European Respiratory Journal suggest that in most settings, the odds of drug resistance are the same for children and adults with TB, consistent with past research.
